Conversion surgery for recurrent hepatic angiosarcoma after systemic chemotherapy with paclitaxel

Clin J Gastroenterol. 2022 Apr;15(2):427-432. doi: 10.1007/s12328-021-01569-2. Epub 2022 Jan 14.

Abstract

A 67-year-old man presented with hemorrhagic shock due to the rupture of hepatic tumor and underwent emergency partial resection of the right liver. Pathological examination revealed hepatic angiosarcoma with involvement in its surgical margin. Six months after the operation, disease recurrence was detected, and he was referred to our hospital for second opinion. CT revealed tumors at the liver cut surface and left lateral segment. The tumor at the liver cut surface abutted to the common bile duct and the portal vein. The tumor was deemed unresectable, and systemic chemotherapy with 4 courses of weekly paclitaxel was given with excellent response. Then, we performed partial liver resection of S4 and S1 with remnant right liver and middle hepatic vein, and wedge resection for the metastatic lesion of segment 3 as a conversion surgery. He developed a grade B bile leakage postoperatively and was discharged on postoperative day 28. He remained disease free for 8 months after the operation.

Keywords: Conversion surgery; Hepatic angiosarcoma; Preoperative chemotherapy.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Hemangiosarcoma* / drug therapy
  • Hemangiosarcoma* / surgery
  • Hepatectomy
  • Humans
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / pathology
  • Liver Neoplasms* / surgery
  • Male
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / surgery
  • Paclitaxel

Substances

  • Paclitaxel